Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
BI

WKN: A3EFRZ | ISIN: US09077D2099 | Ticker: AI10
NASDAQ
19.11.26 | 15:30
0,600 US-Dollar
+0,02 % +0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOFRONTERA INC Chart 1 Jahr
5-Tage-Chart
BIOFRONTERA INC 5-Tage-Chart

Aktuelle News zur BIOFRONTERA INC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOFRONTERA INC Aktie jetzt für 0€ handeln
FrBiofrontera Inc. - 10-Q, Quarterly Report1
FrBiofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth7
FrBiofrontera Inc. - 8-K, Current Report1
07.11.Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 202617
30.10.NSE - Biofrontera Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities8
08.10.Biofrontera Inc.: Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz Red Light PDT to Actinic Keratoses on the Full Body368Submission seeks to extend the Ameluz, label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol WOBURN, Mass....
► Artikel lesen
14.09.Biofrontera Inc. - 8-K, Current Report11
14.09.Biofrontera Inc.: Biofrontera Announces FDA Approval of Ameluz Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma659Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for...
► Artikel lesen
31.08.Biotech Stocks At 52-Week Highs - RenovoRx +12%, BlossomHill Therapeutics, Revvity, AtriCure, Biofrontera Inc.863WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 28, 2026, as various clinical trials reported initial data and companies reached certain regulatory milestones.RenovoRx...
► Artikel lesen
13.08.Biofrontera Inc. - 8-K, Current Report2
13.08.Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth514WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization...
► Artikel lesen
22.07.Biofrontera Inc. - S-8, Securities to be offered to employees in employee benefit plans9
22.07.Biofrontera Inc. - 10-K/A, Annual Report9
17.06.Biofrontera Inc. - 8-K, Current Report10
14.05.Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update641Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy...
► Artikel lesen
19.03.Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update520Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing...
► Artikel lesen
09.03.Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz Photodynamic Therapy for moderate to severe Acne Vulgaris523• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz, PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical...
► Artikel lesen
26.02.Biofrontera Inc.: U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable569WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy ("PDT")...
► Artikel lesen
17.02.Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz for Actinic Keratoses on Trunk and Extremities433Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and...
► Artikel lesen
11.02.Biofrontera Inc.: Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz PDT in Superficial Basal Cell Carcinoma756Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal...
► Artikel lesen
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1